OncoSil Medical
Antonio Ponce Cuesta is an experienced professional in the medical and pharmaceutical sectors, currently serving as the Regional Head for Spain and Portugal at OncoSil Medical since April 2021, focusing on advanced pancreatic cancer treatments. Prior to this role, Antonio held various managerial positions, including Senior Territory Manager at Boston Scientific and Regional Account Manager at BTG plc, specializing in advanced techniques such as radioembolization and cryoablation. With a strong foundation in hematology, oncology, and nephrology, Antonio's career began with key account management roles at Shire and Osteoplac, alongside leadership and sales training from multiple prestigious institutions. Antonio holds several master’s degrees in sales and marketing management and has extensive educational qualifications in medical and commercial fields, including a Bachelor's degree in English Philology.
This person is not in any teams
This person is not in any offices
OncoSil Medical
OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy. OncoSil Medical’s lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel. OncoSil™ is designated as a breakthrough device in both Europe and the United States¹. We believe in our technology and its ability to have a truly positive impact in Oncology. OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications. Website link: oncosil.com References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.